Dose: 0.028 to 0.142 mg/kg
Single Dose: 0.085 (0.085)
Frequency: As recommended.
Route: IM
Instructions: As Required

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

Dose:
Single Dose:
Frequency:
Route:
Instructions: Not recommended in this age group

belongs to Amine. It belongs to Alpha adrenergic agonist pharmacological group on the basis of mechanism of action and also classified in Drugs used in Shock and Vasoconstrictor pharmacological group.The Molecular Weight of Metaraminol is 317.20. It is strongly acidic drug, 5.17% solution of the drug is isotonic and Its pKa is 8.79.

Metaraminol is contraindicated in conditions like Hypersensitivity.

The severe or irreversible adverse effects of Metaraminol, which give rise to further complications include Convulsions, Tachycardia, Confusion, Insomnia, Tissue necrosis, Abscess formation, Sloughing, Tremors.Metaraminol produces potentially life-threatening effects which include Cardiac arrhythmia, Sinus tachycardia, Ventricular tachycardia. which are responsible for the discontinuation of Metaraminol therapy.The signs and symptoms that are produced after the acute overdosage of Metaraminol include Pulmonary edema, Hypertension.The symptomatic adverse reactions produced by Metaraminol are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Anxiety, Dyspnea, Nausea and vomiting.

Metaraminol is primarily indicated in conditions like Acid-related dyspepsia, Acute hypotension, Hypotension, Shock, and can also be given in adjunctive therapy as an alternative drug of choice in Brain tumors, Priapism, Trauma.

Metaraminol is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAmphotericin BDigoxinDihydroergotamine (Mesylate)Dihydroergotamine and metaraminolhve an additive vasoconstriction effect due to alpha adrenergic agonist activity results in great increase in blood pressure.ModerateDihydroergotamine injection or nasal spray is not advised to use or if required then caution must be taken for patient tolerance.Ergotamine (Tartrate)Ergotamine significantly increases the blood pressure by synergistic vasoconstriction due to alpha adrenergic agonist activity of metaraminol.ModerateClinical monitoring of response, tolerence and excessive vasoconstriction is recommended. Patient advised to notify if numbness,tingling,muscle pain,weakness and chest pain signs appears.FurazolidoneCoadministration results hypertension and hyperpyrexia by sympathomimetic effect due to increase norepinephrine storage in neurons and increased release of catecholamine.MajorCoadministration should not be given if necessary then 14 days gap should be given during the initiation of other therapy.GuanethidineGuanethidine work by depleting catecholamines stores from adrenergic nerve endings enhance pharmacologic effect of metaraminol while decrease its hypotensive effect.ModerateMonitoring of blood pressure and heart rate is must if this combination is used.In hypertensive patients noradrenaline is used with caution.MannitolPhenelzineCoadministration involve synergistic sympathomimetic effect because metaraminol enhance noradrenaline storage in adrenergic neurons and phenelzine increased secretion of catecholamines.In some cases death has been reported.other reactions include hyperpyrexia and hypertensive reactions.MajorThis combination should not be used or give a gap of atleast 2 weeks after discontinuing phenelzine to start metaraminol.Tranylcypromine (Sulphate)Coadministration involve synergistic sympathomimetic effect because metaraminol enhance noradrenaline storage in adrenergic neurons and tranylcypromine increased secretion of catecholamines.In some cases death has been reported.MajorThis combination should not be used or give a gap of atleast 2 weeks after discontinuing tranylcypromine to start metaraminol. These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Drug should not be given to Paediatrics, Pregnant Mothers, Geriatrics, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

Inj Store Below 30°C. Do not Freeze. Protect from Sunlight.

Metaraminol should be used with caution in heart disease, thyroid disease, hypertension & diabetes. It should be used in large vein to avoid necrosis & sloughing of surrounding tissues. Cautions should be taken during pregnancy.